|
|
|
|
MoS is clinically distinct from other VGKC-complex antibody-associated conditions, and usually is associated with high-titer CASPR2 antibodies, often accompanied by lower-titer LGl1 antibodies. CASPR2 and LGl1 antibodies bind to multiple brain regions, which helps to explain the multifocal clinical features of the disease, but other antibodies are likely to play a role in some patients need to be characterized in future studies. |
|